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Abstract
Introduction Adjuvant breast cancer therapy significantly
improves survival, but overtreatment and undertreatment are
major problems. Breast cancer expression profiling has so far
mainly been used to identify women with a poor prognosis as
candidates for adjuvant therapy but without demonstrated value
for therapy prediction.
Methods We obtained the gene expression profiles of 159
population-derived breast cancer patients, and used
hierarchical clustering to identify the signature associated with
prognosis and impact of adjuvant therapies, defined as distant
metastasis or death within 5 years. Independent datasets of 76
treated population-derived Swedish patients, 135 untreated
population-derived Swedish patients and 78 Dutch patients
were used for validation. The inclusion and exclusion criteria for
the studies of population-derived Swedish patients were
defined.
Results Among the 159 patients, a subset of 64 genes was
found to give an optimal separation of patients with good and
poor outcomes. Hierarchical clustering revealed three
subgroups: patients who did well with therapy, patients who did
well without therapy, and patients that failed to benefit from
given therapy. The expression profile gave significantly better
prognostication (odds ratio, 4.19; P = 0.007) (breast cancer
end-points odds ratio, 10.64) compared with the Elston–Ellis
histological grading (odds ratio of grade 2 vs 1 and grade 3 vs
1, 2.81 and 3.32 respectively; P = 0.24 and 0.16), tumor stage
(odds ratio of stage 2 vs 1 and stage 3 vs 1, 1.11 and 1.28; P
= 0.83 and 0.68) and age (odds ratio, 0.11; P = 0.55). The risk
groups were consistent and validated in the independent
Swedish and Dutch data sets used with 211 and 78 patients,
respectively.
Conclusion We have identified discriminatory gene expression
signatures working both on untreated and systematically treated
primary breast cancer patients with the potential to spare them
from adjuvant therapy.
CDKN1C = cyclin-dependent kinase inhibitor 1C; CMF = cyclophosphamide, methotrexate and 5-fluorouracil; HOXA5 = homeobox A5; IGF1 = insu-
lin-like growth factor 1.Breast Cancer Research    Vol 7 No 6    Pawitan et al.
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Introduction
Adjuvant systemic therapy saves a significant number of lives
[1-3], but many patients are subjected to unnecessary adju-
vant therapies with the potential of causing more harm than
good [4]. Approximately 25% [5] of all women diagnosed with
breast cancer die from their disease despite having been
treated according to state-of-the-art clinical guidelines [6,7].
The present lack of criteria to help individualize breast cancer
treatment indicates a need for a novel technology to develop
better prognostication and therapy prediction.
The stage, the tumor size and the histological grade are
accepted as prognostic markers for breast cancer [8]. Estro-
gen receptor status, sometimes accompanied by progester-
one receptor status, is the only globally accepted treatment
predictive factor for hormonal therapy for primary breast can-
cer [6]. However, about one-half of the patients with estrogen-
receptor-positive cancer fail on tamoxifen [9,10].
The microarray technology can simultaneously characterize
the RNA expression profile of thousands of genes in a single
tumor. Most microarray studies so far reported have utilized
highly selected patient populations [11-13] and hereditary
breast cancer [14], and few studies have focused on treat-
ment prediction [15]. Prognostication of distant metastases
[16,17] could potentially serve as the basis of patient selection
for adjuvant therapy. There was no guarantee that the high-risk
patients selected for therapy would actually benefit from it,
however, and none of these previous studies addressed the
important problem that a subgroup of women failed to respond
to therapy.
The aim of our project was to use gene expression profiling to
identify patients whose tumors have a low malignant potential,
making adjuvant therapy unnecessary and potentially harmful,
and to identify patients in need of more effective adjuvant ther-
apies. Furthermore, we wanted to show that the expression
profile worked irrespective of primary adjuvant therapy or not
and provided independent information to the established clin-
ical factors.
Materials and methods
Study population
We included all breast cancer patients that were operated on
at the Karolinska Hospital from 1 January 1994 to 31 Decem-
ber 1996 (n  = 524), identified from the population-based
Stockholm–Gotland breast cancer registry established in
1976. Available tumor material was frozen on dry ice or in liq-
uid nitrogen and was stored in -70°C freezers. Figure 1 shows
the details of various exclusions leading to the final 159
patients for analysis. The ethical committee at the Karolinska
Hospital approved this microarray expression project.
The different reasons for exclusion were not influenced by age
at diagnosis (Table 1). The 231 tumors that were not analyzed
using expression profiling had a lower mean diameter, had
fewer mean affected lymph nodes, and had fewer individuals
with recurrent disease at the end of the study period (Table 1).
For those excluded for other reasons, there did not seem to be
a selection based on age or stage of the disease, compared
with those patients included in the study (Table 1).
The Stockholm–Gotland Breast Cancer Registry, supple-
mented with patient records, were examined for information on
the tumor size, the number of retrieved and metastatic axillary
lymph nodes, the hormonal receptor status, distant metas-
tases, the site and date of relapse, initial therapy, therapy for
possible recurrences, the date and cause of death. Tumor sec-
tions from the primary tumors from patients with array profiles
were classified using Elston–Ellis grading [18] by a blinded
pathologist (HN).
In the adjuvant setting tamoxifen and/or goserelin is normally
used for hormonal treatment, but mostly intravenous cyclo-
phosphamide, methotrexate and 5-fluorouracil (CMF) on days
1 and 8 was used as adjuvant chemotherapy, except in high-
risk patients who were offered inclusion in the Scandinavian
Breast Group 9401 study [19]. After primary therapy, patients
were recommended to have regular clinical examinations and
yearly mammograms, in addition to laboratory and X-ray tests
guided by clinical signs and symptoms. Patients were normally
followed for 5 years. Patients followed up outside the Karolin-
ska Hospital were tracked using a unique personal identifica-
tion number. There was no loss to follow-up.
The relapse site, date of relapse, relapse therapy and date of
death were ascertained in May 2002. The average follow-up
was 6.1 years. Cause of death was coded as death due to
breast cancer (including those with distant metastases but
dying from other causes), death due to other malignancies and
death due to nonmalignant disorders. Through the population-
based Swedish Cancer Registry, second primary malignan-
cies were identified.
Validation data
For validation we used population-derived primary breast can-
cer patients receiving primary therapy from 1987 to 1989 in
the county of Uppsala, Sweden [20-22]. From the initial set of
315 patients, representing 65% of all breast cancer patients
in Uppsala county during these years, we were able to obtain
quality-controlled RNA expression profiles from 260 frozen
tumors (including two patients with neoadjuvant tamoxifen)
(Fig. 1). A further follow-up of events was carried out with a
1999 deadline. Seventy-six lymph-node-positive patients
received adjuvant, mostly intravenous, 3-weekly CMF-based
therapy (premenopausal patients) or adjuvant tamoxifen (post-
menopausal patients) [20]. Some node-negative patients also
received adjuvant therapy as previously described [20]. One
hundred and thirty-five node-negative patients did not receive
adjuvant therapy. All tumors have been confirmed to haveAvailable online http://breast-cancer-research.com/content/7/6/R953
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invasive cancer and have been graded according to Elston–
Ellis, except for one patient with missing primary tumor slides
but with the presence of axillary lymph nodes, thus confirming
invasiveness. The ethical committee at the Karolinska Institutet
approved this RNA expression study.
RNA preparation
RNA extraction was performed according to the RNeasy mini
protocol (Qiagen, Hilden, Germany). In brief, a portion of the
deep frozen tumor was cut into minute pieces and transferred
into test tubes (maximum 40 mg/tube) with RLT buffer (RNe-
Figure 1
Description of exclusion criteria for all patients (pts) operated on for primary breast cancer at (a) Karolinska Hospital, 1994–1996 and (b) Uppsala  University Hospital, 1987–1989 Description of exclusion criteria for all patients (pts) operated on for primary breast cancer at (a) Karolinska Hospital, 1994–1996 and (b) Uppsala 
University Hospital, 1987–1989.Breast Cancer Research    Vol 7 No 6    Pawitan et al.
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asy lysis Buffer, Qiagen, Hilden, Germany), followed by
homogenization for around 30–40 s. Proteinase K was then
added and the samples were treated for 10 min at 55°C. This
step was introduced during the project [23] because most ini-
tial preparations without this step resulted in either poor RNA
yield and or poor RNA quality. Total RNA was then isolated
using Qiagen's microspin technology. DNase was also added
to some samples to further increase the RNA quality. The qual-
ity of the RNA was assessed by measuring the 28S:18S ribos-
omal RNA ratio using an Agilent 2100 bioanalyzer (Agilent
Technologies, Rockville, MD, USA). All samples with RNA of
high quality were then stored at -70°C until microarray
analyses.
Microarray profiling
Preparation of in vitro transcription products and oligonucle-
otide array hybridization and scanning were performed
according to the protocol of Affymetrix (Santa Clara, CA,
USA). In brief, the amount of starting total RNA for each probe
preparation varied between 2 and 5 µg. The in vitro transcrip-
tion reactions were performed in batches to generate bioti-
nylated cRNA targets, which were subsequently chemically
fragmented at 95°C for 35 min. Fragmented and biotinylated
cRNA (10 µg) was hybridized at 45°C for 16 hours to Affyme-
trix high-density oligonucleotide array human HG-U133 set
chips. The arrays were washed, and were then stained with
streptavidin–phycoerythrin (final concentration, 10 µg/ml).
The array was then scanned according to the manufacturer's
instructions (Affymetrix Genechip® Technical Manual, 2001;
Affymetrix). The scanned images were inspected for the pres-
ence of obvious defects (artifacts or scratches) on the array. In
the case of visible microarray artifacts, the sample was rehy-
bridized and rescanned on new chips using the same frag-
mented probe. The raw expression data were normalized using
the global mean method [24].
A statistical data filter was applied to reduce noise and to
obtain a useful and relevant probe set to identify markers that
were highly correlated to clinical parameters. The detail is pro-
vided in the Supplementary Report (Additional file 1). This led
to 6573 final probe sets for analysis, consisting of 3393 probe
sets from U133A and 3180 probe sets from U133B. All anal-
yses were performed using natural-log-transformed expres-
sion values.
Primary analysis and validation data sets
The primary statistical analysis was based on comparing good
prognosis and poor prognosis, where poor prognosis was
defined as distant relapse or death from any cause within 5
years of diagnosis. For comparison, a secondary analysis was
performed limiting poor prognosis to distant relapse and death
due to breast cancer. The secondary classification resulted in
seven patients switching from the poor to good prognosis
group.
In order to maximize the statistical power, we initially used the
whole Stockholm cohort (n  = 159) as the training set for
choosing an optimal gene set and identifying risk groups in the
hierarchical cluster analysis. This cohort was a mixture of
patients without adjuvant therapy and 126 patients treated
with CMF, tamoxifen, megesterolacetat, goserelin or some
combinations thereof. We checked the consistency of the
analysis of the whole cohort against the subset of patients
treated with tamoxifen and its combinations (n = 104) and
against all systematically untreated patients (n = 33).
To validate the results we used independent datasets from
Uppsala, consisting of 76 node-positive adjuvant-treated
patients and 135 node-negative untreated patients, and from
the Dutch study of 78 untreated node-negative patients [16],
referred to as the van't Veer data.
Optimal gene selection, definition of the poor-prognosis 
score and statistical analysis
An optimal set of predictors was chosen using a leave-one-out
cross-validation procedure performed on the training set
(Additional file 1). Class prediction using k genes was carried
out using a diagonal linear discriminant analysis method [25],
Table 1
Characteristics of patients operated for breast cancer at the Karolinska Hospital 1994–1996
Patient categories All patients 
(n = 524)
No available tissuea 
(n = 231)
Excluded for other reasonsb 
(n = 134)
Included for analysis 
(n = 159)
Mean age at breast cancer diagnosis (years) 58 57 58 58
Mean tumor size (mm) 20 16 24 22
Proportion of patients with tumor size <21 mm (%) 68 77 57 62
Proportion of patients with positive lymph nodes (%) 26 16 32 38
Proportion deceased (%) 20 12 26 24
aNo frozen tumors in the tumor bank (n = 231).
bLiving abroad (n = 7), actively refused participation (n = 6), degraded tumors (n = 42), insufficient amount of RNA (n = 35), not passed the QC 
for the arrays (n = 12), profiled on the U95 chip (n = 14), neoadjuvant chemotherapy (n = 12), in situ cancer (n = 5) and stage IV at diagnosis (n 
= 1).Available online http://breast-cancer-research.com/content/7/6/R953
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which is a variant of the standard maximum-likelihood
discrimination rule. The class predictor score S is computed
from the top k genes. A patient with S > 0 is assigned to the
poor-prognosis group, and otherwise to the good prognosis
group. We will thus refer to S as the poor-prognostic score or
the risk score.
To investigate whether the risk score had an independent pre-
dictive value over the standard clinical variables, the risk score
S (high–low, with 'high' defined as S > 0) was included in a
multivariate logistic regression analysis with 5-year status as
the outcome variable. To obtain unbiased estimates, the
scores for patients in the training set were computed from the
leave-one-out procedure; because of dependence between
samples, however, this procedure tends to produce optimistic
standard errors [26]. We did not attempt to correct the stand-
ard errors, because the result was also validated in independ-
ent datasets. The clinical variables were the age at diagnosis,
tumor grade, tumor size and lymph node metastasis, estrogen
receptor status (positive–negative) and progesterone recep-
tor status (positive–negative). The tumor size and lymph node
metastases were entered into the model in the form of a stage
variable. These clinical predictors were initially compared
between the good-prognosis and poor-prognosis groups.
Unsupervised hierarchical clustering of the training data was
used to identify flexible risk groups; here we used the Eucli-
dean distance with complete linkage. For validation data, we
used supervised clustering based on the assignment of sam-
ples to the cluster with the closest centroid. The standard
Euclidean distance was used for Uppsala datasets, but for the
van't Veer dataset, because of different scales and possible
outliers, the distance was based on Spearman rank
correlation.
To obtain a better description of the prognosis of the patients
during the follow-up, we also performed survival analysis, ena-
bling us to use full survival information not just the 5-year sta-
tus. The Cox proportional hazard model was used to assess
the additional contribution of the prognosis score after adjust-
ing for the clinical variables.
Results
Clinical characteristics of the patients (n = 159) in this study
(Table 2) showed that those who died or who had distant
metastases (n = 38) more often had tumors ≥ 21 mm in size
(P = 0.06), had a higher mean diameter (P = 0.05), were more
often progesterone-receptor-negative (P  = 0.01) and less
often received endocrine therapy (P = 0.03). No significant dif-
ference was detected in the proportion of patients receiving
chemotherapy or radiotherapy. A similar pattern was observed
when the analyses were limited to breast-cancer-specific
deaths (Additional file 1).
Of the 159 patients in the training set, 38 patients died or
relapsed by 5 years and were thus defined as the poor-prog-
nosis group. Twenty-six of these patients had distant metas-
tases by 5 years, and 12 patients died within 5 years without
diagnosis of distant relapse; six of the 12 deaths were due to
breast cancer. The remaining 121 patients were defined as
the good-prognosis group. Of these patients, after more than
Table 2
Univariate comparison of clinical variables among patients with good prognosis and poor prognosis
Alive (n = 121) Deceased (n = 38) P value
Proportion of patients with poor prognosis score (%) 0.34 0.74 <0.0001
Mean age at breast cancer diagnosis (years) 57.5 (±12.4) 58.8 (±16.8) 0.59
Mean tumor size (mm) 21.3 (±11.5) 25.6 (±12.6) 0.05
Proportion of patients with tumor size <21 mm (%) 0.65 0.47 0.06
Proportion of patients with positive lymph nodes (%) 0.37 0.39 0.71
Proportion of patients with grade I (%) 0.23 0.08 0.06a
Proportion of patients with grade II (%) 0.41 0.36
Proportion of patients with grade III (%) 0.36 0.56
Proportion of patients with estrogen-receptor-positive tumors (%) 0.83 0.79 0.61
Proportion of patients with progesterone-receptor-positive tumors (%) 0.77 0.55 0.01
Proportion of patients receiving chemotherapy (%) 0.18 0.21 0.69
Proportion of patients receiving endocrine therapy (%) 0.76 0.58 0.03
Proportion of patients receiving radiotherapy (%) 0.51 0.39 0.21
Continuous variables compared using t tests; proportions compared using chi-squared tests.
aCombined testing using the chi-squared test.Breast Cancer Research    Vol 7 No 6    Pawitan et al.
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5 years of follow-up, four patients died without recurrence of
breast cancer and four patients had distant relapse.
The leave-one-out procedure (Additional file 1) suggested k =
64 genes as an optimal number of genes for separating the
patients with good prognosis and poor prognosis, giving an
overall error rate of 33%. The list of these genes is presented
in Additional file 1. Among the genes that have higher expres-
sion in tumors with good prognosis, we found cyclin-depend-
ent kinase inhibitor 1 C (CDKN1C), spinal-cord-derived
growth factor B, homeobox A5 (HOXA5) and insulin-like
growth factor 1 (IGF1). Of the genes highly expressed in the
poor-prognosis group we found genes primarily involved in
cell-cycle regulation.
To check whether the expression profile has an independent
predictive value compared with standard clinical factors, we
performed a multivariate logistic regression analysis of the 5-
year status. The results (Table 3) showed high risk associated
with the poor-prognosis score (odds ratio, 4.19; 95% confi-
dence interval, 1.49–11.77) after adjusting for age, stage,
grade, estrogen receptor status and progesterone receptor
status. Of these clinical variables, only progesterone-receptor-
positive status was associated with better prognosis (odds
ratio, 0.35; 95% confidence interval, 0.12–0.99). When we
considered breast cancer endpoints (Additional data 1), the
result for the microarray-based prognostic score is more sig-
nificant than for overall endpoints (odds ratio, 10.64; 95%
confidence interval, 2.91–38.87). The multivariate Cox regres-
sion analysis of the overall and breast cancer endpoints (Addi-
Table 3
Multivariate logistic regression of the 5-year disease free status in relation to the poor-prognosis score and other clinical variables
All events (n = 159) (number of events = 38)
Odds ratio (95% confidence interval) P value
Poor-prognosis score 4.19 (1.49–11.77) 0.007
Age (per 10 years) 1.11 (0.79–1.54) 0.55
Stage
Stage 2 versus 1 1.28 (0.4–4.08) 0.68
Stage 3 versus 1 1.11 (0.42–2.95) 0.83
Elston grade
Grade 2 versus 1 3.32 (0.63–17.56) 0.16
Grade 3 versus 1 2.81 (0.5–15.74) 0.24
Estrogen-receptor-positive 2.94 (0.76–11.28) 0.12
Progesterone-receptor-positive 0.35 (0.12–0.99) 0.05
Figure 2
Unsupervised hierarchical clustering of the Stockholm cohort (n = 159)  using the 64-gene set Unsupervised hierarchical clustering of the Stockholm cohort (n = 159) 
using the 64-gene set. Each column refers to a patient and each row to 
a gene. Red indicates a high value of gene expression, and green indi-
cates a low value. The list of genes is presented in Additional file 1, in 
the same order as they appear on the plot. Risk.score, computed by lin-
ear discriminant analysis and used here only to describe the clusters. 
Status.5 yr, black if the corresponding patient had distant metastasis or 
died within 5 years. BRCA.5 yr, black if the death was due to breast 
cancer. NodePos, black if the corresponding patient was lymph-node-
positive; Grade3, black if the patient had Elston grade 3.Available online http://breast-cancer-research.com/content/7/6/R953
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tional data 1) produced similar results to those of the previous
logistic regression analysis.
The use of the risk score as a classifier offered only a rigid clas-
sification of the patients into good-prognosis and poor-prog-
nosis groups. To overcome this rigidity, we performed a more
flexible classification by hierarchical clustering of 159 patients
using the 64-gene set; here the risk score was only used for a
description of the resulting clusters. The clustering procedure
identified three expression-based subgroups with significantly
distinct prognoses (Fig. 2), arranged from left to right in
increasing risk level. There were 59 patients in the high-risk
cluster, of which 29 patients (49%) had distant metastases or
died within 5 years (Table 4). The subset of the patients
treated with tamoxifen and its combinations (n  = 104)
revealed the high-risk signature in 33 patients, of which 16
patients (48%) had distant metastases or died within 5 years
(Table 4). The high-risk profile was validated by observations
from an independent group of adjuvant-treated patients from
Uppsala (n = 76) (Fig. 3), where 21 out of 35 patients (60%)
from the high-risk cluster had distant metastases or died within
5 years (Table 4). As seen in Fig. 2, the clusters were corre-
lated with tumor grade but not with nodal status.
Among the untreated subgroup from Stockholm (n = 33), 11
out of 16 patients (69%) of the high-risk subgroup reached the
primary endpoint by 5 years (Table 4). Examinations of the
clustering of the untreated patients from Uppsala (n = 135)
(Fig. 4) and from the van't Veer cohort (n = 78) (Fig. 5) indi-
cated that the high-risk cluster had a consistently higher 5-year
event rate than the other clusters in the same cohort (Table 4).
A similar result was obtained for the van't Veer cohort when
the additional 19 patients used for validation in the original
publication [16] were added: 57% of the high-risk group had
a 5-year event rate (data not shown).
To identify women who will do well with or without adjuvant
treatment, we examined the clustering of the untreated
patients in Figs 4 and 5. The rates of death or distant metas-
tases within 5 years were three out of 53 patients (5.7%) and
four out of 25 patients (16%), respectively. Among the treated
groups (Figs 2 and 3), the same expression profile is associ-
ated with the lowest event rates of two out of 49 patients
(4.2%) and two out of 14 patients (14%), respectively, com-
pared with the other clusters (Table 4). In the tamoxifen-
treated subgroup in Stockholm, none of the 38 patients with a
low-risk profile had any event by 5 years (Table 4).
Table 4
Prognosis of the clusters identified in the training and validation sets
Cohort Risk cluster P valuea
Total Low Medium High
Training set
Stockholm n 159 49 51 59
5-year eventb 38 (24%) 2 (4.2%) 7 (14%) 29 (49%) <10-7
Treated with adjuvant therapy
Stockholm tamoxifen only Nc 104 38 33 33
5-year event 22 (21%) 0 (0%) 6 (18%) 16 (48%) <10-6
Uppsala node-positive n 76 14 27 35
5-year event 33 (43%) 2 (14%) 10 (37%) 21 (60%) 0.002
Untreated with adjuvant therapy
Stockholm nc 33 7 10 16
5-year event 11 1 (14%) 0 (0%) 11 (69%) 0.002
Uppsala node-negative n 135 51 55 29
5-year event 17 (12%) 3 (5.8%) 7 (13%) 7 (24%) 0.02
Van't veer n 78d 19 33 25
5-year event 33 2 (17%) 18 (53%) 13 (55%) 0.01
aP value for trend test.
bDistant metastases or death within 5 years.
cSubset of the Stockholm cohort: 82 patients with tamoxifen 2–5 years, eight patients with tamoxifen <2 years, nine patients with tamoxifen in 
sequence with megesterolacetat, and five patients with tamoxifen and goserelin.
dOne patient was removed because of missing data. The 5-year event was distant metastases within 5 years.Breast Cancer Research    Vol 7 No 6    Pawitan et al.
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To summarize, the gene profiling revealed a statistically signif-
icant 5-year outcome result for treated patients in the Stock-
holm (n = 104, P < 10-6) and the Uppsala (n = 76, P = 0.002)
cohorts, respectively (Table 4). The expression profile also
provided similar 5-year outcome data for patients not receiving
adjuvant therapy (Stockholm cohort, n = 33, P = 0.002; van't
Veer cohort, n = 78, P = 0,01; Uppsala cohort, n = 135, P =
0.02) (Table 4).
To gain a better description of the results throughout the fol-
low-up period and across studies, we computed the Kaplan–
Meier survival curves of the risk clusters we found in all data-
sets (Fig. 6). For the high-risk group in all studies, survival
tended to drop fastest in the first 5 years after surgery and to
level off after 5 years. This means that the 5-year survival rate
provided the best comparison between risk clusters. The
results were mainly consistent across studies and confirmed
the expected survival patterns of risk groups (Fig. 6). For the
node-negative untreated Uppsala patients (Fig. 6c), the lack of
significance is due to the convergence of the survival curves
at around 8 years after surgery. If we limit the comparison to 5-
year survival, the survival curves are significantly different (i.e.
consistent with the result in Table 4).
Discussion
Several consensus documents [6,7] have underlined the lack
of useful prognostic and predictive factors beyond tumor size,
axillary lymph node status, histological grade and hormone
receptor status. Our expression profile, consisting of 64
genes, was better than those in clinical use today, including
the factors histological grade, tumor stage and age. Using
gene expression profiling we were able to stratify patients into
those that did well and where treatment did not appear to con-
tribute, and into those with an aggressive tumor who failed to
respond or developed resistance to the used adjuvant
therapies.
Analysis of adjuvant-treated and untreated groups
Our analytic approach improved the previous studies of breast
cancer prognosis using microarray gene expression data by
jointly analyzing adjuvant-treated patients and untreated
patients. A previous Dutch study identified 70 prognostic
genes from an analysis of untreated patients [16], but
provided no indication of who might fail to respond to adjuvant
therapy. Other studies involving treated patients also did not
discuss the treatment assessment [27].
Figure 3
Supervised clustering of the node-positive treated cohort in Uppsala (n  = 76) using the 64-gene set Supervised clustering of the node-positive treated cohort in Uppsala (n 
= 76) using the 64-gene set. The accompanying variables have the 
same meaning as in Fig. 2.
Figure 4
Supervised clustering of the node-negative untreated cohort in Uppsala  (n = 135) using the 64-gene set Supervised clustering of the node-negative untreated cohort in Uppsala 
(n = 135) using the 64-gene set. The accompanying variables have the 
same meaning as in Fig. 2.Available online http://breast-cancer-research.com/content/7/6/R953
R961
Any evaluation of adjuvant therapy must consider three types
of patients: type A, those patients who do well without
treatment; type B, those patients who do poorly without treat-
ment, but may benefit from treatment; and type C, those
patients who do poorly despite treatment. It is clear that type-
A patients should not be treated, while type-C patients require
new treatment protocols that were not available during the
study periods 1987–1989 and 1994–1996, respectively. Our
results indicate that the low-risk cluster consists mostly of
type-A patients and the high-risk cluster consists mostly of
type-C patients. The medium-risk group does not provide such
clear information. In the present study we identified that
around 30% of the patients in the Stockholm cohort were of
low risk, hence requiring no adjuvant therapy, and that almost
40% were of high risk, for whom the existing adjuvant therapy
failed. Almost three-quarters of the patients therefore did not
benefit from treatment. To our knowledge, no previous study
has stated this as explicitly.
One weakness of the current study as well as all of the previ-
ous studies is the inability of the gene expression profile to
identify patients that will actually benefit from treatment (type-
B patients). Without a randomized trial, this goal appears diffi-
cult to reach.
Molecular biology of the markers
Twenty-two of the 64 genes have unknown function, while the
other genes represent various biological pathways such as
DNA replication and transcription, cell-cycle regulation, cell
adhesion and metastasis (Table 5). Among the genes associ-
ated with low-risk tumors we found CDKN1C, PDGFD, IGF1,
HOXA5, SLIT2 and PTN, and many of the genes associated
with high-risk tumors appeared to be involved in cell-cycle reg-
ulation (including CDC2, CDC20, BUB1B, PRC1 and RRM2)
and in transcription (such as TOP2A).
Some of the genes have been reported to be involved in breast
cancer. CDKN1C, a tumor suppressor gene that regulates cell
proliferation, was recently found to be downregulated in meta-
static tumors [28]. Circulating IGF1 levels are associated with
increased breast cancer risk [29]. The HOXA5 gene has been
shown to play an important role in breast tumorigenesis. Its
expression is higher in normal breast epithelium than in breast
carcinomas, and expression of HOXA5 is lost in over 60% of
breast tumors and cell lines, largely due to methylation, while
its overexpression has been shown to induce apoptosis [30].
HOXA5 functions as a positive regulator of p53 transcription,
and breast cancer cell lines and breast tumors display a coor-
dinate loss of p53 and HOXA5 mRNA and protein expression
[31]. Other direct targets of HOXA5 are the progesterone
receptor and PTN genes. Microarray analysis has shown sig-
nificantly lower expression of pleiotrophin in breast
carcinomas [32,33]. In agreement with this, both HOXA5 and
Figure 5
Supervised clustering of the van't Veer cohort (n = 78) using 42 genes  of the 64-gene set Supervised clustering of the van't Veer cohort (n = 78) using 42 genes 
of the 64-gene set. Meta.5 yr, black if the patient had distant metastasis 
within 5 years.
Figure 6
Kaplan–Meier survival curves of the risk clusters found in (a) the Stock- holm cohort, (b) the Uppsala treated cohort, (c) the Uppsala untreated  cohort and (d) the van't Veer cohort Kaplan–Meier survival curves of the risk clusters found in (a) the Stock-
holm cohort, (b) the Uppsala treated cohort, (c) the Uppsala untreated 
cohort and (d) the van't Veer cohort. L, low-risk group; M, medium-risk 
group; H, high-risk group. The P value in each plot, computed in a Cox 
regression, is for simultaneous comparison of all three curves for the 
whole follow-up period.Breast Cancer Research    Vol 7 No 6    Pawitan et al.
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PTN were associated with the low-risk tumors in our data set.
SLIT2 is also a potential tumor suppressor gene. Promoter
methylation associated with reduced SLIT2 expression was
found in 43% of breast tumors [34]. The TOP2A gene, which
was associated with the high-risk tumors, was recently identi-
fied as one of the genes of a general cancer metasignature
[35]. TOP2A has an essential role in DNA replication and is a
molecular target for many anticancer drugs. In breast cancer,
gene copy aberrations of the TOP2A gene have been
detected [36].
Only three of the 64 genes in our study were among the 70
genes found to have a prognostic value identified by van't Veer
and colleagues [16]: LOC51203, PRC1 and L2DTL. Table 5
compares the gene functions according to the gene ontology.
To obtain an assessment of genome-wide correlation, we
obtained the t statistics from 6434 genes in common between
the Stockholm and van't Veer cohorts, and obtained a correla-
tion of 0.31. The lack of strong correlation is probably not sur-
prising, as there are several differences between the two
studies. Firstly, the tumors analyzed came from different
patient cohorts; the Stockholm and Uppsala cohorts were
population-derived with clearly described inclusion and exclu-
sion criteria (Fig. 1), while the van't Veer cohort of lymph-node-
negative patients were preselected to have a distant recur-
rence versus no relapse within 5 years. Secondly, different
gene expression platforms were used in the two studies, prob-
ably resulting in both different initial gene sets being quantified
and examined, and in different relative quantification values for
a given gene. Thirdly, different methodologies may have been
used in tumor archiving and RNA preparation. Finally, different
statistical and filtering approaches were used to obtain a sub-
set of genes that make up the best prognostic gene sets.
Conclusion
The adjuvant therapy experienced by the patients in this study
included CMF for the premenopausal patients and tamoxifen
for the postmenopausal patients. The use of anthracycline-
based and taxane-based therapy and more optimal endocrine
therapy strategies might alter the distribution of patients, espe-
cially moving individuals from type C to type B [37-41], as
experienced with the Her-2 status and adjuvant anthracycline
therapy [42]. Our results would suggest that the individuals
who would potentially benefit from aggressive therapies with
anthracyclines or taxanes would be primarily those identified
by our classifier as the high-risk cluster, but that has to be
investigated in a prospective study.
In summary, using the expression profiles of 64 genes we
developed a prognostication of breast cancer patients after
surgery. We identified that almost three-quarters of early
breast cancer patients might not benefit from adjuvant therapy
because of superior outcome or because of failing to respond
to current adjuvant therapy. With recent molecular studies
showing that breast cancer consists of a number of different
subgroups with unique prognostic properties, the
conventional management of breast cancer patients seems
ripe for improvement.
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